GPC-1 may serve as a predictor of perineural invasion and a prognosticator of survival in pancreatic cancer

Duan, Lian; Hu, X G; Feng, Deyun; Lei, Shi-yue; Hu, Guo‐Huang

doi:10.1016/j.asjsur.2012.08.001

Cited by 64 publications

(57 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another important clinical use could be the prediction of survival of PC patients, indeed Melo and associates, using a Cox multivariate regression analysis documented that the decrease of circulating GPC1 exosomes as an independent prognostic marker predictive for disease-specific survival. This result confirms previous finding by Duan and coauthors, who reported that GPC1 is significantly related to the perineural invasion in PC and it has an independent prognostic effect on the overall survivals (36).…”

Section: Commentarysupporting

confidence: 93%

Glypican-1 exosomes: do they initiate a new era for early pancreatic cancer diagnosis?

Lorenzon¹,

Blandino²

2016

Transl. Gastroenterol. Hepatol.

View full text Add to dashboard Cite

Section: Commentarysupporting

confidence: 93%

Glypican-1 exosomes: do they initiate a new era for early pancreatic cancer diagnosis?

Lorenzon¹,

Blandino²

2016

Transl. Gastroenterol. Hepatol.

View full text Add to dashboard Cite

“…Importantly, anti‐GPC1 mAb also induced potent tumor growth inhibition in xenograft models using patient‐derived GPC1‐positive ESCC tumors, suggesting that GPC1 would be a promising therapeutic target in ESCC. Elevated expression of GPC1 has been reported in breast cancer, glioblastoma and pancreatic cancer . Expression levels of GPC1 have not, however, been evaluated in uterine cervical cancer.…”

mentioning

confidence: 99%

“…Elevated expression of GPC1 has been reported in breast cancer, glioblastoma and pancreatic cancer. [19][20][21][22][23] Expression levels of GPC1 have not, however, been evaluated in uterine cervical cancer.…”

mentioning

confidence: 99%

Anti‐glypican‐1 antibody‐drug conjugate exhibits potent preclinical antitumor activity against glypican‐1 positive uterine cervical cancer

Matsuzaki

Serada

Hiramatsu

et al. 2017

Intl Journal of Cancer

View full text Add to dashboard Cite

Glypican-1 (GPC1) is highly expressed in solid tumors, especially squamous cell carcinomas (SCCs), and is thought to be associated with disease progression. We explored the use of a GPC1-targeted antibody-drug conjugate (ADC) as a novel treatment for uterine cervical cancer. On immunohistochemical staining, high expression levels of GPC1 were detected in about 50% of uterine cervical cancer tissues and also in a tumor that had relapsed after chemoradiotherapy. Novel anti-GPC1 monoclonal antibodies were developed, and clone 01a033 was selected as the best antibody for targeted delivery of the cytotoxic agent monomethyl auristatin F (MMAF) into GPC1-positive cells. The anti-GPC1 antibody was conjugated with MMAF. On flow cytometry, HeLa and ME180 cervical cancer cells highly expressed GPC1, however, RMG-I ovarian clear cell cancer cell line showed weak expression. The GPC1-ADC was rapidly internalized into GPC1-expressing cells in vitro and was potently cytotoxic to cancer cells highly expressing GPC1. There were no inhibitory effects on cancer cells with low expression of GPC1. In a murine xenograft model, GPC1-ADC also had significant and potent tumor growth inhibition. GPC1-ADC-mediated G2/M phase cell cycle arrest was detected, indicating that the dominant antitumor effect in vivo was MMAF-mediated. The toxicity of GPC-ADC was tolerable within the therapeutic dose range in mice. Our data showed that GPC1-ADC has potential as a promising therapy for uterine cervical cancer.

show abstract

“…Regarding the MMPs, we were able to verify that GPC1 was positively correlated with MMP expression, which may reveal a role of the PG in GBM invasiveness. It has been suggested that MMP9 could bind to GPCs and possibly with GPC1 [17,31]. Nevertheless, there is no data on whether GPCs could influence MMP2 expression nor a more thorough description of how these expressions would be altered in different kinds of cancer, such as GBM.…”

Section: Discussionmentioning

confidence: 99%

“…Glypican-1 (GPC1) is, along with other GPCs, bound to the membrane through a glycosylphosphatidylinositol (GPI) anchor [9]. It is ubiquitous and influences cellcell and cell-matrix adhesion, metastasis, invasion, and proliferation in various tumors, such as breast, pancreatic, and esophageal cancers [10][11][12][13][14][15][16][17][18]. Although GPC1 has received little focus in regard to glioblastoma, Saito & colleagues demonstrated how this molecule influences the lower survival of GBM patients [19].…”

Section: Research Paper Wwwoncotargetcommentioning

confidence: 99%

Glypican-1 in human glioblastoma: implications in tumorigenesis and chemotherapy

Listik

Toma

2020

Oncotarget

View full text Add to dashboard Cite

Glioblastoma is one of the most common malignant brain tumors, with which patients have a mean survival of 24 months. Glypican-1 has been previously shown to be overexpressed in human glioblastoma and to be negatively correlated with patient's survival. This study aimed to investigate how glypican-1 influences the tumoral profile of human glioblastoma using in vitro cell line models. By downregulating the expression of glypican-1 in U-251 MG cells, we observed that the cellular growth and proliferation were highly reduced, in which cells were significantly shifted towards G0 as opposed to G1 phases. Cellular migration was severely affected, and glypican-1 majorly impacted the affinity towards laminin-binding of glioblastoma U-251 MG cells. This proteoglycan was highly prevalent in glioblastoma cells, being primarily localized in the cellular membrane and extracellular vesicles, occasionally with glypican-3. Glypican-1 could also be found in cell-cell junctions with syndecan-4 but was not identified in lipid rafts in this study. Glypican-1-silenced cells were much more susceptible to temozolomide than in U-251 MG itself. Therefore, we present evidence not only to support facts that glypican-1 is an elementary macromolecule in glioblastoma tumoral microenvironment but also to introduce this proteoglycan as a promising therapeutic target for this lethal tumor.

show abstract

GPC-1 may serve as a predictor of perineural invasion and a prognosticator of survival in pancreatic cancer

Abstract: GPC-1 is significantly related to the perineural invasion of pancreatic cancer, holding some prognostic significance in patients with pancreatic cancer.

Cited by 64 publications

References 20 publications

Glypican-1 exosomes: do they initiate a new era for early pancreatic cancer diagnosis?

Glypican-1 exosomes: do they initiate a new era for early pancreatic cancer diagnosis?

Anti‐glypican‐1 antibody‐drug conjugate exhibits potent preclinical antitumor activity against glypican‐1 positive uterine cervical cancer

Glypican-1 in human glioblastoma: implications in tumorigenesis and chemotherapy

Contact Info

Product

Resources

About